Queens Hospital Cancer Center

Jamaica, New York 11432

2 studies enrolling now · 6 studies all time

What they study most

Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer, Locally Advanced or Metastatic Breast Cancer, Non-small Cell Lung Cancer, Sickle Cell Anemia, Sickle Cell Disease

Studies at this site

• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) — Running, not enrolling
• Open-Label Extension Study to Pioneer Study 6058-SCD-101 — Enrolling by invitation
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir — Completed
• Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) — Running, not enrolling
• A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label — Stopped early